Bkemv (Eculizumab-Aeeb) for PNH

Overview
Bkemv is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (the destruction of red blood cells). Eligiblility for this treatment typically depends on having a diagnosis of PNH confirmed by specific laboratory tests. Bkemv is also known by its drug name, eculizumab-aeeb.

Bkemv is a biologic drug that inhibits a part of the immune system known as the complement system, which is overactive in PNH. By blocking this system, Bkemv helps prevent the destruction of red blood cells.

How do I take it?
Prescribing information states that Bkemv is administered through intravenous infusion. The recommended dosing schedule for PNH involves an initial phase where the drug is given weekly for the first five weeks, followed by a maintenance phase where the drug is administered every two weeks. Bkemv should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Bkemv include headache, nasopharyngitis (inflammation of the nasal passages and throat), back pain, and nausea.

Rare but serious side effects may include serious meningococcal infections (infections caused by Neisseria meningitidis). Individuals who are at increased risk for these infections even with vaccination and should be monitored for early signs and symptoms of infection.

For more information about this treatment, visit:

Bkemv (Eculizumab-Aeeb) Injection, for Intravenous Use — U.S. Food and Drug Administration

Bkemv — Drugs.com